{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:44:15Z","timestamp":1788965055853,"version":"build-2803163510"},"reference-count":24,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background: Several thrombotic risk assessment models have been proposed for identifying patients with a high risk of thrombosis (the IMPEDE venous thromboembolism (VTE), SAVED, and PRISM scores) in multiple myeloma (MM). Recently, adding a biomarker (D-dimer) for the IMPEDE VTE score has shown that it can boost the detection power of IMPEDED VTE. However, data from studies comparing these models in MM are scarce. Even real-world data arguing the utility of thrombotic risk assessment models in MM from low- or middle-income countries like T\u00fcrkiye are lacking. Methods: We aimed to show the possibility of detecting VTE using the IMPEDED VTE score in our cohort by retrospectively screening MM patients. Therefore, we aimed to compare the IMPEDE VTE, SAVED and IMPEDED VTE scoring models. Results: We conducted a retrospective analysis of 455 MM patients from three centers in Bursa, T\u00fcrkiye, evaluating the incidence of VTE within six months of the treatment. The IMPEDED VTE score showed superior predictive accuracy (c-statistic of 0.701), compared to the IMPEDE VTE (0.618) and SAVED (0.633) scores, demonstrating the added value of D-dimer as a biomarker. The cumulative incidence of VTE in the cohort was 10.7%, comparable to rates observed in real-world studies. Conclusions: Despite the interventions and thrombotic risk assessment models, thrombosis remains a high-risk entity. Personalized risk assessment tools, such as IMPEDED VTE, could be used to manage thrombotic risk in MM patients, particularly in resource-limited settings. Albeit the thromboprophylaxis (51.6%), our findings support the utility of biomarker-enhanced models for better VTE-risk stratification, particularly in resource-limited settings.<\/jats:p>","DOI":"10.3390\/diagnostics15050633","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T06:02:13Z","timestamp":1741240933000},"page":"633","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparative Analysis and Validation of the IMPEDED VTE, IMPEDE VTE, and SAVED Risk Models in Predicting Venous Thromboembolism in Multiple Myeloma Patients: A Retrospective Study in T\u00fcrkiye"],"prefix":"10.3390","volume":"15","author":[{"given":"Vildan","family":"Gursoy","sequence":"first","affiliation":[{"name":"The Division of Hematology, The Department of Internal Medicine, The Faculty of Medicine, Uludag University, 16059 Bursa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7681-4623","authenticated-orcid":false,"given":"Mehmet","family":"Baysal","sequence":"additional","affiliation":[{"name":"The Department of Hematology, Tekirdag \u0130. Fehmi Cumalioglu City Hospital, 59030 Tekirdag, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevil","family":"Sadri","sequence":"additional","affiliation":[{"name":"The Division of Hematology, The Department of Internal Medicine, Bursa City Hospital, 16250 Bursa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4991-9830","authenticated-orcid":false,"given":"Fazil Cagri","family":"Hunutlu","sequence":"additional","affiliation":[{"name":"The Division of Hematology, The Department of Internal Medicine, The Faculty of Medicine, Uludag University, 16059 Bursa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5419-3221","authenticated-orcid":false,"given":"Tuba","family":"Ersal","sequence":"additional","affiliation":[{"name":"The Division of Hematology, The Department of Internal Medicine, The Faculty of Medicine, Uludag University, 16059 Bursa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozgur Omer","family":"Gul","sequence":"additional","affiliation":[{"name":"The Department of Internal Medicine, Bursa City Hospital, 16250 Bursa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Kose","sequence":"additional","affiliation":[{"name":"The Department of Internal Medicine, Bursa City Hospital, 16250 Bursa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra","family":"Celik","sequence":"additional","affiliation":[{"name":"The Department of Internal Medicine, The Faculty of Medicine, Uludag University, 16059 Bursa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serap","family":"Baysal","sequence":"additional","affiliation":[{"name":"The Department of Public Health, The Faculty of Medicine, Tekirdag Nam\u0131k Kemal University, 59030 Tekirdag, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu\u011fba","family":"Gullu Koca","sequence":"additional","affiliation":[{"name":"The Division of Hematology, The Department of Internal Medicine, The Faculty of Medicine, Uludag University, 16059 Bursa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinem","family":"Cubukcu","sequence":"additional","affiliation":[{"name":"The Division of Hematology, The Department of Internal Medicine, The Faculty of Medicine, Uludag University, 16059 Bursa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezel","family":"Ergun","sequence":"additional","affiliation":[{"name":"The Division of Hematology, The Department of Internal Medicine, The Faculty of Medicine, Uludag University, 16059 Bursa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyma","family":"Yavuz","sequence":"additional","affiliation":[{"name":"The Division of Hematology, The Department of Internal Medicine, The Faculty of Medicine, Uludag University, 16059 Bursa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vildan","family":"Ozkocaman","sequence":"additional","affiliation":[{"name":"The Division of Hematology, The Department of Internal Medicine, The Faculty of Medicine, Uludag University, 16059 Bursa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9710-134X","authenticated-orcid":false,"given":"Fahir","family":"Ozkalemkas","sequence":"additional","affiliation":[{"name":"The Division of Hematology, The Department of Internal Medicine, The Faculty of Medicine, Uludag University, 16059 Bursa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1055\/s-0034-1370793","article-title":"Venous thromboembolism in multiple myeloma","volume":"40","author":"Za","year":"2014","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3324\/haematol.2012.064444","article-title":"Thrombosis is associated with inferior survival in multiple myeloma","volume":"97","author":"Kristinsson","year":"2012","journal-title":"Haematologica"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1182\/blood-2002-01-0335","article-title":"Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: Implications for therapy","volume":"100","author":"Zangari","year":"2002","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.4065\/80.12.1549","article-title":"Thalidomide therapy and deep venous thrombosis in multiple myeloma","volume":"80","author":"Rajkumar","year":"2005","journal-title":"Mayo Clin. Proc."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/cncr.23336","article-title":"Thromboembolic events with lenalidomide-based therapy for multiple myeloma","volume":"112","author":"Menon","year":"2008","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/rth2.12411","article-title":"Venous thromboembolism in multiple myeloma is associated with increased mortality","volume":"4","author":"Schoen","year":"2020","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1080\/10428194.2022.2092856","article-title":"Thromboprophylaxis in multiple myeloma","volume":"63","author":"Thalambedu","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"840","DOI":"10.6004\/jnccn.2018.7273","article-title":"Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-Associated Thrombosis Among Patients With Multiple Myeloma","volume":"17","author":"Li","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.25603","article-title":"Predicting venous thromboembolism in multiple myeloma: Development and validation of the IMPEDE VTE score","volume":"94","author":"Sanfilippo","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1182\/blood.2022015727","article-title":"Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: Derivation and validation of the PRISM score","volume":"140","author":"Chakraborty","year":"2022","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"102235","DOI":"10.1016\/j.rpth.2023.102235","article-title":"D-dimer predicts venous thromboembolism in multiple myeloma: A nested case-control study","volume":"7","author":"Sanfilippo","year":"2023","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/leu.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma","volume":"28","author":"Chng","year":"2014","journal-title":"Leukemia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1111\/bjh.17505","article-title":"Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: A retrospective cohort study","volume":"193","author":"Covut","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/bjh.18630","article-title":"External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs","volume":"201","author":"Dima","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood.2020005125","article-title":"Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials","volume":"136","author":"Bradbury","year":"2020","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e2045172","DOI":"10.1097\/01.HS9.0000970812.20451.72","article-title":"P977: The venous thromboembolism risk assesment models in multiple myeloma","volume":"7","author":"Kirkizlar","year":"2023","journal-title":"HemaSphere"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.1002\/ajh.25658","article-title":"Predicting the risk of venous thromboembolism in newly diagnosed myeloma with immunomodulatory drugs: External validation of the IMPEDE VTE score","volume":"95","author":"Chalayer","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.thromres.2023.11.021","article-title":"Venous thromboembolism prophylaxis and multiple myeloma patients in real-life: Results of a large survey and clinical guidance recommendations from the IFM group","volume":"233","author":"Frenzel","year":"2024","journal-title":"Thromb. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"102571","DOI":"10.1016\/j.rpth.2024.102571","article-title":"Multiple myeloma: Retrospective assessment of routine thromboprophylaxis and utility of thrombotic risk scores","volume":"8","author":"Amezcua","year":"2024","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/bjh.18432","article-title":"Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study","volume":"199","author":"Sborov","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11239-023-02817-7","article-title":"Comparison of three risk assessment models for thromboembolism in multiple myeloma patients receiving immunomodulators: A Brazilian historical cohort","volume":"56","author":"Silveira","year":"2023","journal-title":"J. Thromb. Thrombolysis"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/5\/633\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:47:52Z","timestamp":1760028472000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/5\/633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":24,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["diagnostics15050633"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics15050633","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]}}}